Industries de la santé
CMC Biologics and Genexine Announce Manufacturing Agreement for Genexine's Human Growth Hormone Drug, GX-H9
21 Février 2017
BOTHELL, Washington, U.S.A., and SEONGNAM, Republic of Korea, February 21, 2017 – CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Genexine, Inc. (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, today announced that they have entered into a... |Plus d'articles...
- Pixium Vision reçoit le Statut-1 de remboursement innovation NUB pour IRIS®II, son système de vision bionique doté de 150 électrodes, en Allemagne
- Hepatitis C market to see steady decline as high cure rates in major markets curb patient populations
- Digital trends are changing marketing strategies within the pharmaceutical field
- BIOCORP : Eric Dessertenne est nommé Directeur Général Délégué